fashion -WSS

fashion

author：entertainment 2025-09-06 04:38:07 - browse：417

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Medicare wants to send $9 billion to 340B hospitals

explore

WSS

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Obesity now affects over 1 billion people worldwide, study finds

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

FogPharma raises $145 million in rare Series E round

Kenai launches with $82 million for Parkinson’s stem cell therapy

Kenai launches with $82 million for Parkinson’s stem cell therapy

entertainment

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Teachers share how revamped forgiveness program helped with their student loans

Medical leaders decry Supreme Court decision on affirmative action

Change Healthcare cyberattack outage could last weeks

In Memoriam: Notable people who died in 2023

Why getting cancer drugs just got harder for rural patients

Anesthesiologist group: stop taking Ozempic before surgery

A Q&A with Aletha Maybank, AMA’s chief health equity officer

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

leisure time

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Swim instructor mom warns parents not to buy blue swimsuits for kids

Pandemic and All Hazards Preparedness Act needs lean update

Judge agrees to delay next hearing in Trump classified documents case

Eisai exec who led development of Alzheimer’s drug to retire

FDA does about

leisure time

focus

explore

hotspot